ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Autism spectrum disorder (ASD) in children and adolescents: Terminology, epidemiology, and pathogenesis

Autism spectrum disorder (ASD) in children and adolescents: Terminology, epidemiology, and pathogenesis
Literature review current through: May 2024.
This topic last updated: Jan 24, 2024.

INTRODUCTION — Autism spectrum disorder (ASD) is a biologically based neurodevelopmental disorder characterized by persistent deficits in social communication and social interaction and restricted, repetitive patterns of behavior, interests, and activities.

The terminology, epidemiology, and pathogenesis of ASD will be reviewed here. Surveillance and screening, clinical features, diagnosis, and management of ASD are discussed separately.

(See "Autism spectrum disorder in children and adolescents: Surveillance and screening in primary care".)

(See "Autism spectrum disorder in children and adolescents: Clinical features".)

(See "Autism spectrum disorder in children and adolescents: Evaluation and diagnosis".)

(See "Autism spectrum disorder in children and adolescents: Overview of management".)

TERMINOLOGY — The terminology and diagnostic criteria for ASD vary geographically.

The Diagnostic and Statistical Manual of Mental Disorders (DSM) is used predominantly in the United States and was updated in 2022 (DSM-5-Text Revision [DSM-5-TR]) [1].

The World Health Organization International Classification of Diseases, 11th Revision (ICD-11) is used in other countries throughout the world [2]. The 11th revision was implemented in 2022.

With the 2022 implementation, ICD-11 changed the terminology for ASD to be consistent with that in DSM-5 and DSM-5-TR [2,3]. ASD is the "parent" term and is further characterized by the presence or absence of a disorder of intellectual development and/or impairment or absence of functional language. In ICD-10, ASD was classified as a "pervasive developmental disorder" with several subtypes (eg, childhood autism, atypical autism, and Asperger syndrome).

In both systems, ASD is characterized by [1,4]:

Persistent deficits in social communication and reciprocal social interaction (eg, deficits in social reciprocity; nonverbal communicative behaviors; and skills in developing, maintaining, and understanding relationships), and

Restricted, repetitive, and inflexible patterns of behavior, interests, or activities

The symptoms must be present in early development. However, because symptoms may not be apparent until social demands exceed limited capacities, no age threshold for "early development" is specified. The symptoms also must substantially impair functioning in personal, social, educational, occupational, or other important areas.

The diagnosis of ASD is qualified by a number of specifiers, including the presence or absence of associated conditions (eg, intellectual impairment, language impairment). The DSM-5-TR also includes qualifiers for three levels of severity, which are rated separately for social communication and restricted, repetitive behaviors) [1].

The diagnostic criteria for ASD are similar, but not identical, in DSM-5-TR and ICD-11 [3]. They are discussed separately. (See "Autism spectrum disorder in children and adolescents: Evaluation and diagnosis", section on 'Diagnostic criteria'.)

EPIDEMIOLOGY

Prevalence — Estimates of the prevalence of ASD vary with study methodology and the population that is evaluated. The overall prevalence of ASD in Europe, Asia, and the United States ranges from 2 to 25 per 1000, or approximately 1 in 40 to 1 in 500 [5-20].

Three national databases are used to estimate ASD prevalence in the United States:

The Autism and Developmental Disabilities Monitoring (ADDM) Network identifies ASD through screening and abstraction of existing health and education records among eight-year-old children at selected study sites. For 2020, the surveillance case definition included any of the following: an ASD diagnostic statement in an evaluation, a classification of ASD in special education, or an ASD International Classification of Diseases code [20].

In 2020, the estimated prevalence was 27.6 per 1000 (1 in 36) eight-year-old children overall, 1 in 23 males, and 1 in 88 females [20]. The prevalence estimates varied from 23.1 to 29.8 per 1000 children between sites, except for California, where the prevalence was 44.9 per 1000. Compared with prior years, 2020 was the first year that prevalence was lower in White children (24.3 per 1000) than in all other racial and ethnic groups.

The Early ADDM Network identifies ASD through screening and abstraction of existing health and education records among four-year-old and eight-year-old children at selected study sites. The Early ADDM Network uses similar case definitions as the ADDM Network described above.

In 2020, the estimated prevalence was 21.5 per 1000 (1 in 47) four-year-old children overall, 1 in 31 males, and 1 in 96 females [21]. Prevalence estimates varied widely by site and by race/ethnicity (16.3 per 1000 among non-Hispanic White children, 25.3 per 1000 non-Hispanic Black children, 28.7 per 1000 among Hispanic children, and 23.5 among Asian/Pacific Islander children). Evaluations for autism decreased during the coronavirus disease 2019 (COVID-19) pandemic. Screening levels recovered but had not returned to baseline by the end of this surveillance period.

The National Health Interview Survey (NHIS) estimates the prevalence of ASD in children age 3 through 17 years according to parent report of a clinician diagnosis [15]. In the 2016 NHIS, the estimated prevalence of ASD was 25 per 1000 (95% CI 22.3-28.1 per 1000): approximately 1 in 40 children overall, 1 in 26 males, and 1 in 93 females.

The prevalence of ASD has increased over time, particularly since the late 1990s [22-24]. Systematic reviews of epidemiologic studies suggest that changes in case definition and increased awareness account for much of the apparent increase [22,25-28]. Other factors that may play a role include earlier detection, availability of more specialized developmental services, diagnostic substitution (ie, increases in prevalence of ASD accompanied by decreases in the prevalence of learning disorders, developmental language disorder, and/or intellectual disability [ID]), as well as a true increase in prevalence [10,25,27,29-35].

Male-to-female ratio — ASD is three to four times more common in males than females [17,24,36,37]. In a systematic review of 54 studies including >13,700,000 patients, the overall male-to-female ratio was 4.2 (95% CI 3.8-4.6) [36]. However, in higher-quality studies and in studies that screened the general population for cases of ASD, the male-to-female ratio was closer to 3, suggesting that ASD may be underdiagnosed in females.

Rate in siblings — The estimated prevalence of ASD in siblings of a child with ASD who does not have an associated medical condition or syndrome is approximately 10 percent (range 4 to 14 percent) [38-41]. However, in some studies, the prevalence of ASD in siblings of children with ASD is as high as 20 percent [38,42,43].

Younger male siblings of a child with ASD are more often affected than younger female siblings, but the risk of recurrence appears to be increased when the index patient is a female. An administrative database study evaluated the recurrence of ASD among children in >1.5 million families with two children age 4 to 18 years between 2008 and 2016 [43]. The overall prevalence of ASD was 1.25 percent. Among the families in which the older child had ASD, the risk of recurrence varied as follows according to the sex of the siblings:

Younger brothers of females with ASD – 17 percent

Younger brothers of males with ASD – 13 percent

Younger sisters of females with ASD – 8 percent

Younger sisters of males with ASD – 4 percent

The 2013 American College of Medical Genetics and Genomics practice guideline provides the following risks for ASD in siblings of children with ASD without an identifiable etiology: 7 percent if the affected child is female, 4 percent if the affected child is male, and ≥30 percent if there are two or more affected children [38,44,45].

Siblings of children with ASD may have symptoms of ASD even if they do not meet criteria for diagnosis of ASD (sometimes called the "broad ASD phenotype"). In observational studies, symptoms of ASD or associated neurodevelopmental abnormalities were more common among siblings of ASD than siblings of children without ASD [41,46-52].

Associated conditions and syndromes — A number of neurodevelopmental problems and genetic syndromes are associated with ASD [1]. Approximately 33 to 45 percent of patients with ASD have ID, as many as 50 percent have attention deficit hyperactivity disorder, and as many as 30 percent have epilepsy [23,24,53-55]. The risk of epilepsy is increased in patients with more severe ID [40].

Up to 25 percent of cases of ASD are associated with a genetic cause, many of which have well-characterized clinical features (eg, tuberous sclerosis complex [TSC], valproate embryopathy, 15q chromosome duplication) [56-61]. Associated syndromes are more common in patients with global developmental delay or ID. Any genetic syndrome that has been associated with ID can also be associated with ASD (eg, Down syndrome) [62]. Genetic diagnoses commonly associated with ASD include (table 1) [23,40,56,63,64]:

Tuberous sclerosis complex – TSC is an inherited neurocutaneous disorder that is characterized by the development of variety of benign tumors in multiple organs. Associated clinical features include hypopigmented macules (picture 1A-B), angiofibromas (picture 2), shagreen patches (picture 3), seizures, and cognitive deficits. Approximately 40 percent of patients with TSC also have ASD; however, only 0.4 to 4 percent of patients with ASD have TSC [65-68]. Patients with comorbid TSC and ASD often have epilepsy [65,67,69,70]. (See "Tuberous sclerosis complex: Clinical features".)

Fragile X syndrome – Fragile X syndrome is an X-linked disorder that is often associated with ID. Characteristic features of the classic phenotype include a long, narrow face, prominent forehead and chin, large ears, testicular enlargement in adolescence, macrocephaly, arched palate, and hyperextensible joints. In a systematic review, 30 percent of males with fragile X syndrome had features of ASD [68]. However, fragile X syndrome is rarely found in patients with ASD [71-73]. (See "Fragile X syndrome: Clinical features and diagnosis in children and adolescents".)

Chromosome 15q11-q13 duplication syndrome – Chromosome 15 q11-q13 duplication syndrome is characterized by hypotonia, joint laxity, global (especially motor) developmental delays, seizures, speech delay, social deficits, stereotypies, and a variable pattern of mild facial dysmorphisms [74,75]. 15q11-q13 duplication has been reported in approximately 1 to 2 percent of children with ASD, usually those with moderate to profound ID [63,76-79]. (See "Microduplication syndromes", section on '15q11-13 duplication syndrome'.)

Angelman syndrome – Angelman syndrome is a neurodevelopmental disorder characterized by severe ID, postnatal microcephaly, and movement or balance problems. It is caused by absence of the maternally inherited copy of the UBE3A gene, which maps to chromosome 15q11-q13. In a systematic review, 34 percent of patients with Angelman syndrome had ASD [68]. (See "Microdeletion syndromes (chromosomes 12 to 22)", section on '15q11-13 maternal deletion syndrome (Angelman syndrome)'.)

Rett syndrome – Classic Rett syndrome occurs almost exclusively in females. It is characterized by loss of speech, replacement of purposeful hand movement with stereotypic hand movement, gait abnormalities, and an abnormal respiratory pattern. In a systematic review, approximately 60 percent of females with Rett syndrome had phenomenology of ASD [68]. (See "Rett syndrome: Genetics, clinical features, and diagnosis".)

Cohen syndrome – Clinical features of Cohen syndrome include characteristic facial features (eg, thick hair and eyebrows, wave-shaped palpebral fissures, broad nasal tip, short or smooth philtrum), microcephaly, poor weight gain in infancy, truncal obesity in adolescence, hypotonia, developmental delay, neutropenia, and joint hypermobility [80]. In a systematic review, approximately 54 percent of patients with Cohen syndrome had phenomenology of ASD [68].

Cornelia de Lange syndrome – Cornelia de Lange syndrome is characterized by distinctive facial features (microcephaly, synophrys, highly arched eyebrows, anteverted nares), prenatal onset growth delay, hirsutism, and upper-limb reduction deficits [81]. Associated findings include hearing impairment, myopia, cardiac septal defects, gastrointestinal dysfunction, and genitourinary abnormalities. In a systematic review, approximately 43 percent of patients with Cornelia de Lange syndrome had phenomenology of ASD [68].

Neurofibromatosis type 1 – Neurofibromatosis type 1 (NF1) is characterized by multiple café-au-lait macules (picture 4), axillary and/or inguinal freckling, Lisch nodules (iris hamartomas), and neurofibromas (picture 5). In a systematic review, approximately 18 percent of patients with NF1 had phenomenology of ASD [68]. (See "Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis", section on 'Clinical manifestations'.)

Down syndrome – Down syndrome is characterized by a variety of dysmorphic features (eg, upslanting palpebral fissures, epicanthic folds, brachycephaly), congenital malformations (eg, transverse palmar crease), ID, and other medical conditions (eg, cardiovascular disease, gastrointestinal abnormalities, endocrine disorders). In a systematic review, approximately 16 percent of patients with Down syndrome had phenomenology of ASD [68]. (See "Down syndrome: Clinical features and diagnosis".)

Noonan syndrome – Noonan syndrome is a clinically and genetically heterogeneous condition that is associated with short stature and congenital heart disease (most often pulmonic stenosis) and delayed development. In a systematic review, approximately 15 percent of patients with Noonan syndrome had phenomenology of ASD [68]. (See "Noonan syndrome", section on 'Clinical manifestations'.)

Williams-Beuren syndrome – Williams-Beuren syndrome is a multisystemic genetic disorder with variable phenotypic expression that is associated with "elfin" facies, systemic arterial stenosis (most often supravalvular aortic stenosis), short stature, genitourinary abnormalities, and impaired cognition and development. In a systematic review, approximately 12 percent of patients with Williams-Beuren syndrome had phenomenology of ASD [68]. (See "Williams syndrome", section on 'Clinical manifestations'.)

DiGeorge (22q11.2 deletion) syndrome – The classic presentation of DiGeorge syndrome includes conotruncal cardiac anomalies, hypoplastic thymus, and hypocalcemia; however, the phenotype is variable (table 2). In a systematic review, approximately 11 percent of patients with 22q11.2 deletion syndrome had phenomenology of ASD [68]. (See "DiGeorge (22q11.2 deletion) syndrome: Clinical features and diagnosis".)

PTEN (phosphatase and tensin homolog gene)-associated macrocephaly syndromes; PTEN-associated macrocephaly syndromes include:

Macrocephaly/autism syndrome – Clinical features of macrocephaly/autism syndrome include postnatal macrocephaly, broad forehead, frontal bossing, long philtrum, depressed nasal bridge, and ID.

Cowden/Bannayan-Riley-Ruvalcaba syndrome – Clinical features of Cowden syndrome include macrocephaly, birdlike facies, hypoplastic mandible and maxilla, cataract, microstomia, high-arched palate, pectus excavatum, genitourinary anomalies, skin tags, lipomas, and penile macules.

(See "PTEN hamartoma tumor syndromes, including Cowden syndrome", section on 'Autism spectrum disorders and macrocephaly'.)

CHARGE syndrome – CHARGE syndrome is characterized by coloboma of the eye, heart defects, choanal atresia, growth retardation, genitourinary anomalies, and ear abnormalities. As many as 50 percent of affected patients have ASD [23,68].

Joubert syndrome – Joubert syndrome is a heterogeneous syndrome characterized by hypoplasia of the cerebellar vermis, neurologic symptoms (eg, dysregulation of breathing pattern, developmental delay), retinal dystrophy, and kidney anomalies. Approximately 40 percent of patients with Joubert syndrome also have ASD [23]. (See "Clinical manifestations, diagnosis, and treatment of nephronophthisis", section on 'Joubert syndrome'.)

Smith-Lemli-Opitz syndrome – Smith-Lemli-Opitz syndrome is an autosomal recessive disorder of cholesterol biosynthesis [40]. Clinical features include postnatal microcephaly, soft cleft palate/bifid uvula, micrognathia, low-set posteriorly rotated ears, poor weight gain, syndactyly of the second and third toes, abnormal genitalia, ID, hypotonia, and autistic features (eg, deficits in social interaction and communication, repetitive and stereotyped behaviors) [82,83]. In one case series, 10 to 12 of 14 children with Smith-Lemli-Opitz syndrome met criteria for ASD [82].

Timothy syndrome – Timothy syndrome is characterized by syndactyly, congenital heart disease, multiorgan dysfunction, and cognitive abnormalities. As many as 70 percent of patients with Timothy syndrome also have ASD [23].

Genetic syndromes that are not well characterized clinically may account for as many as 20 percent of cases of ASD [56]. These syndromes are characterized by incomplete penetrance and variable expressivity – which makes them difficult to identify clinically. Although there is some overlap with clinically defined syndromes, examples of such syndromes include chromosomal variations (eg, isodicentric 15q), ASD-associated copy-number variants (eg, 16p11.2 deletions or duplications), and pathogenic variants of ASD-risk genes (eg, CHD8 [chromosome helicase deoxyribonucleic acid (DNA) binding protein 8]).

PATHOGENESIS

Genetic factors — The pathogenesis of ASD is incompletely understood. The general consensus is that ASD is caused by genetic factors that alter brain development, specifically neural connectivity, thereby affecting social communication development and leading to restricted interests and repetitive behaviors [84-87]. This consensus is supported by the "epigenetic theory," in which an abnormal gene is turned "on" early in fetal development and affects the expression of other genes without changing their primary DNA sequence [88,89]. In a multinational, population-based cohort study including more than 2 million children, approximately 1 percent of whom were diagnosed with ASD by age 16 years, the estimated median heritability of ASD was 81 percent (95% CI 73-86 percent) [90]. (See "Principles of epigenetics".)

Given the complexity of ASD and the diversity of clinical manifestations, it is likely that interactions between multiple genes or gene combinations are responsible for ASD and that epigenetic factors and exposure to environmental modifiers contribute to the variable expression [91-96]. ASD has been associated with polygenic variants, single nucleotide variants, copy number variants, rare inherited variants, tandem repeats, and noncoding variants [56,86,96-101]. (See "Genetics: Glossary of terms" and 'Associated conditions and syndromes' above.)

A strong genetic contribution to the development of ASD is supported by the unequal sex distribution, increased prevalence in siblings, high concordance in monozygotic twins, and increased risk of ASD with increased relatedness [39,51,91,92,96,102-106]. In a large population-based study, the cumulative risk of ASD by age 20 years was approximately 3 percent for cousins, 7 percent for paternal half-siblings, 9 percent for maternal half-siblings, 13 percent for full siblings and dizygotic twins, and 59 percent for monozygotic twins [39]. (See 'Male-to-female ratio' above and 'Rate in siblings' above.)

Although male predominance suggests X-linkage, male-to-male transmission in a number of families excludes X-linkage as the only mode of inheritance [91,107]. The prevalence among siblings of patients with ASD is higher than the prevalence in the general population [91,108-110] but much lower than would be expected for single-gene diseases [91]. (See 'Male-to-female ratio' above and 'Rate in siblings' above.)

The correlation between clinical phenotypes and specific genetic profiles continues to be investigated. Although linkage studies and whole exome sequencing have identified many genetic variations predisposing to ASD [44,56,111,112], no individual variation accounts for >1 percent of cases of ASD and no specific mutation is unique to ASD [40]. (See 'Associated conditions and syndromes' above.)

Neurobiologic factors — Neuroimaging, electrophysiology, and autopsy studies in patients with ASD suggest that brain abnormalities, particularly atypical neural connectivity, play an important role in the development of ASD [23,113].

Children with ASD may have accelerated head growth during infancy and increased overall brain size [114,115]. (See "Autism spectrum disorder in children and adolescents: Clinical features", section on 'Macrocephaly'.)

Compared with individuals without ASD, individuals with ASD have different total and regional gray and white matter volumes, sulcal and gyral anatomy, brain chemical concentrations, neural networks, cortical structure and organization, and brain lateralization [116-123]. Cortical changes appear to result from abnormal neuronal differentiation during prenatal development [122]. Individuals with ASD use different patterns of connectivity, cognitive strategies, and brain areas to process information during tasks requiring social attribution (eg, faces, eye gaze, speech) and social and nonsocial rewards than individuals without ASD [124-135].

Parental age — Advanced parental age (both paternal and maternal) has been associated with an increased risk of having a child with ASD [136-142]. The age comparisons vary from study to study but typically range from ≥30 to 35 years versus <30 years for mothers and ≥40 years versus <30 years for fathers. The association between advanced parental age and increased risk of having a child with ASD is perhaps related to de novo spontaneous mutations and/or alterations in genetic imprinting [143]. (See "Inheritance patterns of monogenic disorders (Mendelian and non-Mendelian)", section on 'Parent-of-origin effects (imprinting)'.)

Environmental and perinatal factors — Environmental factors include toxic exposures, teratogens, perinatal insults, and prenatal infections. They account for few cases of ASD but may constitute a "second-hit," modulating existing genetic factors predisposing to ASD [40,86,144,145]. The effects of environmental exposures appear to depend on the timing and duration of exposure, concentration of the toxin, mechanism of action, and distribution in the central nervous system.

A meta-analysis of 40 heterogeneous observational studies of perinatal and neonatal risk factors for autism found little evidence to implicate any single factor in the etiology of autism [146]. However, there was some evidence to suggest that the broad class of conditions that compromise perinatal and neonatal health (eg, abnormal presentation, low birth weight, meconium aspiration) may increase the risk. A subsequent meta-analysis of observational studies supports an increased risk of ASD in preterm infants [147]. Subsequent observational studies also suggest that maternal conditions (eg, diabetes, obesity, hypertension, preeclampsia) are associated with increased risk of ASD [148-153].

Maternal medication use during pregnancy — The potential role of maternal medication use during pregnancy in the development of ASD is discussed separately. (See "Antenatal exposure to selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs): Risk of autism in the offspring" and "Risks associated with epilepsy during pregnancy and the postpartum period", section on 'Risks with specific ASMs'.)

Lack of association with immunizations — Epidemiologic evidence does not support an association between immunizations and ASD. (See "Autism spectrum disorder and chronic disease: No evidence for vaccines or thimerosal as a contributing factor".)

DEVELOPMENTAL TRAJECTORY — Few studies have evaluated the developmental trajectory of ASD [154,155]. This diagnostic category was first introduced with the publication of the Diagnostic and Statistical Manual for Mental Disorders, Fifth Edition (DSM-5) in 2013. The prior version of the DSM included autistic disorder, Asperger disorder, and pervasive developmental disorder, which were replaced with the creation of the ASD category in the DSM-5.

In a study conducted after publication of the DSM-5, 213 children (36 girls and 177 boys) diagnosed with ASD between the ages of 18 to 36 months were reevaluated between the ages of five to seven years using a research assessment [156]. Seventy-nine (37 percent) no longer met criteria for an ASD diagnosis. Nonpersistence was associated with higher baseline adaptive skills and female sex.

INFORMATION FOR PATIENTS — UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.

Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword[s] of interest.)

Basics topic (see "Patient education: Autism spectrum disorder (The Basics)")

Beyond the Basics topic (see "Patient education: Autism spectrum disorder (Beyond the Basics)")

SUMMARY

Terminology – Autism spectrum disorder (ASD) is a biologically based neurodevelopmental disorder characterized by persistent deficits in social communication and interaction and restricted, repetitive patterns of behavior, interests, or activities. Symptoms become apparent when social demands exceed limited capacities. Severity is determined by functional impairment and can be critical in the ability to access services. (See 'Terminology' above.)

Prevalence – Estimates of prevalence vary with study methodology and the population that is evaluated and range from 1 in 40 to 1 in 500. The prevalence of ASD has increased over time, particularly since the late 1990s, primarily as a result of changes in case definition and increased awareness. In the United States, national surveillance suggests a prevalence of approximately 1 in 40 to 1 in 60. (See 'Prevalence' above.)

Associated conditions and syndromes – Intellectual disability, attention deficit hyperactivity disorder, and epilepsy are common in children with ASD. ASD is more common among children with certain genetic conditions than in the general population (table 1). These conditions include tuberous sclerosis complex, fragile X syndrome, chromosome 15q11-13 duplication syndrome, Angelman syndrome, Rett syndrome, Down syndrome, Cohen syndrome, Cornelia de Lange syndrome, Neurofibromatosis type 1, Noonan syndrome, Williams-Beuren syndrome, DiGeorge (22q11.2 deletion) syndrome, PTEN-associated macrocephaly syndrome, CHARGE syndrome, Joubert syndrome, Smith-Lemli-Opitz syndrome, and Timothy syndrome. (See 'Associated conditions and syndromes' above.)

Pathogenesis – The pathogenesis of ASD is incompletely understood. The general consensus is that ASD is caused by genetic factors that alter brain development resulting in the neurobehavioral phenotype. Environmental and perinatal factors account for few cases of ASD but may modulate underlying genetic factors. (See 'Pathogenesis' above.)

The overwhelming majority of epidemiologic evidence does not support an association between immunizations and ASD. (See "Autism spectrum disorder and chronic disease: No evidence for vaccines or thimerosal as a contributing factor".)

  1. American Psychiatric Association. Autism spectrum disorder. In: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision, American Psychiatric Association, Washington, DC 2022. p.56.
  2. World Health Organization. ICD-11 International Classification of Diseases 11th Revision. https://www.who.int/classifications/classification-of-diseases (Accessed on April 20, 2022).
  3. First MB, Gaebel W, Maj M, et al. An organization- and category-level comparison of diagnostic requirements for mental disorders in ICD-11 and DSM-5. World Psychiatry 2021; 20:34.
  4. 6A02 Autism spectrum disorder. In ICD-11 for Mortality and Morbidity Statistics (Version 2/2022) https://icd.who.int/browse11/l-m/en#/http%3a%2f%2fid.who.int%2ficd%2fentity%2f437815624 (Accessed on April 20, 2022).
  5. Baird G, Simonoff E, Pickles A, et al. Prevalence of disorders of the autism spectrum in a population cohort of children in South Thames: the Special Needs and Autism Project (SNAP). Lancet 2006; 368:210.
  6. Webb E, Morey J, Thompsen W, et al. Prevalence of autistic spectrum disorder in children attending mainstream schools in a Welsh education authority. Dev Med Child Neurol 2003; 45:377.
  7. Williams E, Thomas K, Sidebotham H, Emond A. Prevalence and characteristics of autistic spectrum disorders in the ALSPAC cohort. Dev Med Child Neurol 2008; 50:672.
  8. Chien IC, Lin CH, Chou YJ, Chou P. Prevalence and incidence of autism spectrum disorders among national health insurance enrollees in Taiwan from 1996 to 2005. J Child Neurol 2011; 26:830.
  9. Surén P, Bakken IJ, Aase H, et al. Autism spectrum disorder, ADHD, epilepsy, and cerebral palsy in Norwegian children. Pediatrics 2012; 130:e152.
  10. Zablotsky B, Black LI, Maenner MJ, et al. Estimated Prevalence of Autism and Other Developmental Disabilities Following Questionnaire Changes in the 2014 National Health Interview Survey. Natl Health Stat Report 2015; :1.
  11. Kim YS, Leventhal BL, Koh YJ, et al. Prevalence of autism spectrum disorders in a total population sample. Am J Psychiatry 2011; 168:904.
  12. Xu G, Strathearn L, Liu B, Bao W. Prevalence of Autism Spectrum Disorder Among US Children and Adolescents, 2014-2016. JAMA 2018; 319:81.
  13. Brugha TS, Spiers N, Bankart J, et al. Epidemiology of autism in adults across age groups and ability levels. Br J Psychiatry 2016; 209:498.
  14. Schendel DE, Thorsteinsson E. Cumulative Incidence of Autism Into Adulthood for Birth Cohorts in Denmark, 1980-2012. JAMA 2018; 320:1811.
  15. Kogan MD, Vladutiu CJ, Schieve LA, et al. The Prevalence of Parent-Reported Autism Spectrum Disorder Among US Children. Pediatrics 2018; 142.
  16. Xu G, Strathearn L, Liu B, et al. Prevalence and Treatment Patterns of Autism Spectrum Disorder in the United States, 2016. JAMA Pediatr 2019; 173:153.
  17. Shaw KA, Maenner MJ, Bakian AV, et al. Early Identification of Autism Spectrum Disorder Among Children Aged 4 Years - Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2018. MMWR Surveill Summ 2021; 70:1.
  18. Zhou H, Xu X, Yan W, et al. Prevalence of Autism Spectrum Disorder in China: A Nationwide Multi-center Population-based Study Among Children Aged 6 to 12 Years. Neurosci Bull 2020; 36:961.
  19. Sasayama D, Kuge R, Toibana Y, Honda H. Trends in Autism Spectrum Disorder Diagnoses in Japan, 2009 to 2019. JAMA Netw Open 2021; 4:e219234.
  20. Maenner MJ, Warren Z, Williams AR, et al. Prevalence and Characteristics of Autism Spectrum Disorder Among Children Aged 8 Years - Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2020. MMWR Surveill Summ 2023; 72:1.
  21. Shaw KA, Bilder DA, McArthur D, et al. Early Identification of Autism Spectrum Disorder Among Children Aged 4 Years - Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2020. MMWR Surveill Summ 2023; 72:1.
  22. Williams JG, Higgins JP, Brayne CE. Systematic review of prevalence studies of autism spectrum disorders. Arch Dis Child 2006; 91:8.
  23. Lai MC, Lombardo MV, Baron-Cohen S. Autism. Lancet 2014; 383:896.
  24. Maenner MJ, Shaw KA, Bakian AV, et al. Prevalence and Characteristics of Autism Spectrum Disorder Among Children Aged 8 Years - Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2018. MMWR Surveill Summ 2021; 70:1.
  25. Fombonne E. Epidemiology of pervasive developmental disorders. Pediatr Res 2009; 65:591.
  26. Wing L, Potter D. The epidemiology of autistic spectrum disorders: is the prevalence rising? Ment Retard Dev Disabil Res Rev 2002; 8:151.
  27. Shattuck PT. The contribution of diagnostic substitution to the growing administrative prevalence of autism in US special education. Pediatrics 2006; 117:1028.
  28. Baxter AJ, Brugha TS, Erskine HE, et al. The epidemiology and global burden of autism spectrum disorders. Psychol Med 2015; 45:601.
  29. Zablotsky B, Black LI, Maenner MJ, et al. Estimated prevalence of autism and other developmental disabilities following questionnaire changes in the 2014 National Health Interview Survey. National Health Statistics Reports No. 87, 2015. http://www.cdc.gov/nchs/products/nhsr.htm (Accessed on November 18, 2015).
  30. Croen LA, Grether JK, Hoogstrate J, Selvin S. The changing prevalence of autism in California. J Autism Dev Disord 2002; 32:207.
  31. Barbaresi WJ, Katusic SK, Colligan RC, et al. The incidence of autism in Olmsted County, Minnesota, 1976-1997: results from a population-based study. Arch Pediatr Adolesc Med 2005; 159:37.
  32. Mandell DS, Palmer R. Differences among states in the identification of autistic spectrum disorders. Arch Pediatr Adolesc Med 2005; 159:266.
  33. Bishop DV, Whitehouse AJ, Watt HJ, Line EA. Autism and diagnostic substitution: evidence from a study of adults with a history of developmental language disorder. Dev Med Child Neurol 2008; 50:341.
  34. Parner ET, Schendel DE, Thorsen P. Autism prevalence trends over time in Denmark: changes in prevalence and age at diagnosis. Arch Pediatr Adolesc Med 2008; 162:1150.
  35. Hertz-Picciotto I, Delwiche L. The rise in autism and the role of age at diagnosis. Epidemiology 2009; 20:84.
  36. Loomes R, Hull L, Mandy WPL. What Is the Male-to-Female Ratio in Autism Spectrum Disorder? A Systematic Review and Meta-Analysis. J Am Acad Child Adolesc Psychiatry 2017; 56:466.
  37. Zablotsky B, Black LI, Maenner MJ, et al. Prevalence and Trends of Developmental Disabilities among Children in the United States: 2009-2017. Pediatrics 2019; 144.
  38. Ozonoff S, Young GS, Carter A, et al. Recurrence risk for autism spectrum disorders: a Baby Siblings Research Consortium study. Pediatrics 2011; 128:e488.
  39. Sandin S, Lichtenstein P, Kuja-Halkola R, et al. The familial risk of autism. JAMA 2014; 311:1770.
  40. Hyman SL, Levy SE, Myers SM, COUNCIL ON CHILDREN WITH DISABILITIES, SECTION ON DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS. Identification, Evaluation, and Management of Children With Autism Spectrum Disorder. Pediatrics 2020; 145.
  41. Jokiranta-Olkoniemi E, Cheslack-Postava K, Sucksdorff D, et al. Risk of Psychiatric and Neurodevelopmental Disorders Among Siblings of Probands With Autism Spectrum Disorders. JAMA Psychiatry 2016; 73:622.
  42. Constantino JN, Zhang Y, Frazier T, et al. Sibling recurrence and the genetic epidemiology of autism. Am J Psychiatry 2010; 167:1349.
  43. Palmer N, Beam A, Agniel D, et al. Association of Sex With Recurrence of Autism Spectrum Disorder Among Siblings. JAMA Pediatr 2017; 171:1107.
  44. Schaefer GB, Mendelsohn NJ, Professional Practice and Guidelines Committee. Clinical genetics evaluation in identifying the etiology of autism spectrum disorders: 2013 guideline revisions. Genet Med 2013; 15:399.
  45. Simonoff E. Genetic counseling in autism and pervasive developmental disorders. J Autism Dev Disord 1998; 28:447.
  46. Yirmiya N, Gamliel I, Shaked M, Sigman M. Cognitive and verbal abilities of 24- to 36-month-old siblings of children with autism. J Autism Dev Disord 2007; 37:218.
  47. Piven J, Palmer P, Jacobi D, et al. Broader autism phenotype: evidence from a family history study of multiple-incidence autism families. Am J Psychiatry 1997; 154:185.
  48. Dalton KM, Nacewicz BM, Alexander AL, Davidson RJ. Gaze-fixation, brain activation, and amygdala volume in unaffected siblings of individuals with autism. Biol Psychiatry 2007; 61:512.
  49. Gamliel I, Yirmiya N, Jaffe DH, et al. Developmental trajectories in siblings of children with autism: cognition and language from 4 months to 7 years. J Autism Dev Disord 2009; 39:1131.
  50. Gamliel I, Yirmiya N, Sigman M. The development of young siblings of children with autism from 4 to 54 months. J Autism Dev Disord 2007; 37:171.
  51. Miller M, Musser ED, Young GS, et al. Sibling Recurrence Risk and Cross-aggregation of Attention-Deficit/Hyperactivity Disorder and Autism Spectrum Disorder. JAMA Pediatr 2019; 173:147.
  52. Lindgren KA, Folstein SE, Tomblin JB, Tager-Flusberg H. Language and reading abilities of children with autism spectrum disorders and specific language impairment and their first-degree relatives. Autism Res 2009; 2:22.
  53. Leitner Y. The co-occurrence of autism and attention deficit hyperactivity disorder in children - what do we know? Front Hum Neurosci 2014; 8:268.
  54. Lukmanji S, Manji SA, Kadhim S, et al. The co-occurrence of epilepsy and autism: A systematic review. Epilepsy Behav 2019; 98:238.
  55. Simonoff E, Pickles A, Charman T, et al. Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample. J Am Acad Child Adolesc Psychiatry 2008; 47:921.
  56. Fernandez BA, Scherer SW. Syndromic autism spectrum disorders: moving from a clinically defined to a molecularly defined approach. Dialogues Clin Neurosci 2017; 19:353.
  57. Chakrabarti S, Fombonne E. Pervasive developmental disorders in preschool children. JAMA 2001; 285:3093.
  58. Chakrabarti S, Fombonne E. Pervasive developmental disorders in preschool children: confirmation of high prevalence. Am J Psychiatry 2005; 162:1133.
  59. Gillberg C, Coleman M. Autism and medical disorders: a review of the literature. Dev Med Child Neurol 1996; 38:191.
  60. Battaglia A, Carey JC. Etiologic yield of autistic spectrum disorders: a prospective study. Am J Med Genet C Semin Med Genet 2006; 142C:3.
  61. Rutter M, Bailey A, Bolton P, Le Couteur A. Autism and known medical conditions: myth and substance. J Child Psychol Psychiatry 1994; 35:311.
  62. Oxelgren UW, Myrelid Å, Annerén G, et al. Prevalence of autism and attention-deficit-hyperactivity disorder in Down syndrome: a population-based study. Dev Med Child Neurol 2017; 59:276.
  63. Filipek PA, Accardo PJ, Ashwal S, et al. Practice parameter: screening and diagnosis of autism: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Child Neurology Society. Neurology 2000; 55:468.
  64. Cohen D, Pichard N, Tordjman S, et al. Specific genetic disorders and autism: clinical contribution towards their identification. J Autism Dev Disord 2005; 35:103.
  65. Smalley SL. Autism and tuberous sclerosis. J Autism Dev Disord 1998; 28:407.
  66. Wong V. Study of the relationship between tuberous sclerosis complex and autistic disorder. J Child Neurol 2006; 21:199.
  67. Numis AL, Major P, Montenegro MA, et al. Identification of risk factors for autism spectrum disorders in tuberous sclerosis complex. Neurology 2011; 76:981.
  68. Richards C, Jones C, Groves L, et al. Prevalence of autism spectrum disorder phenomenology in genetic disorders: a systematic review and meta-analysis. Lancet Psychiatry 2015; 2:909.
  69. Gillberg IC, Gillberg C, Ahlsén G. Autistic behaviour and attention deficits in tuberous sclerosis: a population-based study. Dev Med Child Neurol 1994; 36:50.
  70. Curatolo P, Cusmai R, Cortesi F, et al. Neuropsychiatric aspects of tuberous sclerosis. Ann N Y Acad Sci 1991; 615:8.
  71. Weinstein V, Tanpaiboon P, Chapman KA, et al. Do the data really support ordering fragile X testing as a first-tier test without clinical features? Genet Med 2017; 19:1317.
  72. Mullegama SV, Klein SD, Nguyen DC, et al. Is it time to retire fragile X testing as a first-tier test for developmental delay, intellectual disability, and autism spectrum disorder? Genet Med 2017; 19.
  73. Hartley T, Potter R, Badalato L, et al. Fragile X testing as a second-tier test. Genet Med 2017; 19.
  74. Bolton PF, Dennis NR, Browne CE, et al. The phenotypic manifestations of interstitial duplications of proximal 15q with special reference to the autistic spectrum disorders. Am J Med Genet 2001; 105:675.
  75. Battaglia A, Parrini B, Tancredi R. The behavioral phenotype of the idic(15) syndrome. Am J Med Genet C Semin Med Genet 2010; 154C:448.
  76. Cook EH Jr, Lindgren V, Leventhal BL, et al. Autism or atypical autism in maternally but not paternally derived proximal 15q duplication. Am J Hum Genet 1997; 60:928.
  77. Wolpert CM, Menold MM, Bass MP, et al. Three probands with autistic disorder and isodicentric chromosome 15. Am J Med Genet 2000; 96:365.
  78. Baker P, Piven J, Schwartz S, Patil S. Brief report: duplication of chromosome 15q11-13 in two individuals with autistic disorder. J Autism Dev Disord 1994; 24:529.
  79. Nurmi EL, Dowd M, Tadevosyan-Leyfer O, et al. Exploratory subsetting of autism families based on savant skills improves evidence of genetic linkage to 15q11-q13. J Am Acad Child Adolesc Psychiatry 2003; 42:856.
  80. Wang H, Falk MJ, Wensel C, et al. Cohen Syndrome. In GeneReviews, Ardinger HH, Pagon RA, et al (eds). University of Washington, Seattle, August 2006 [Updated July 2016 Jul 21]. Available at: https://www.ncbi.nlm.nih.gov/books/NBK1482 (Accessed on April 28, 2020).
  81. Deardorff MA, Noon SE, Krantz ID. Cornelia de Lange Syndrome. In GeneReviews, Ardinger HH, Pagon RA, et al (eds). University of Washington, Seattle, 2005 [Updated January 2016 Jan 28]. Available at: https://www.ncbi.nlm.nih.gov/books/NBK1104 (Accessed on April 28, 2020).
  82. Sikora DM, Pettit-Kekel K, Penfield J, et al. The near universal presence of autism spectrum disorders in children with Smith-Lemli-Opitz syndrome. Am J Med Genet A 2006; 140:1511.
  83. Bukelis I, Porter FD, Zimmerman AW, Tierney E. Smith-Lemli-Opitz syndrome and autism spectrum disorder. Am J Psychiatry 2007; 164:1655.
  84. Baron-Cohen S. Two new theories of autism: hyper-systemising and assortative mating. Arch Dis Child 2006; 91:2.
  85. Ecker C, Bookheimer SY, Murphy DG. Neuroimaging in autism spectrum disorder: brain structure and function across the lifespan. Lancet Neurol 2015; 14:1121.
  86. Muhle RA, Reed HE, Stratigos KA, Veenstra-VanderWeele J. The Emerging Clinical Neuroscience of Autism Spectrum Disorder: A Review. JAMA Psychiatry 2018; 75:514.
  87. Geschwind DH. Genetics of autism spectrum disorders. Trends Cogn Sci 2011; 15:409.
  88. Samaco RC, Nagarajan RP, Braunschweig D, LaSalle JM. Multiple pathways regulate MeCP2 expression in normal brain development and exhibit defects in autism-spectrum disorders. Hum Mol Genet 2004; 13:629.
  89. Lopez-Rangel E, Lewis ME. Loud and clear evidence for gene silencing by epigenetic mechanisms in autism spectrum and related neurodevelopmental disorders. Clin Genet 2006; 69:21.
  90. Bai D, Yip BHK, Windham GC, et al. Association of Genetic and Environmental Factors With Autism in a 5-Country Cohort. JAMA Psychiatry 2019; 76:1035.
  91. Muhle R, Trentacoste SV, Rapin I. The genetics of autism. Pediatrics 2004; 113:e472.
  92. Hallmayer J, Cleveland S, Torres A, et al. Genetic heritability and shared environmental factors among twin pairs with autism. Arch Gen Psychiatry 2011; 68:1095.
  93. Bacchelli E, Maestrini E. Autism spectrum disorders: molecular genetic advances. Am J Med Genet C Semin Med Genet 2006; 142C:13.
  94. Sahin M, Sur M. Genes, circuits, and precision therapies for autism and related neurodevelopmental disorders. Science 2015; 350.
  95. Yuen RK, Thiruvahindrapuram B, Merico D, et al. Whole-genome sequencing of quartet families with autism spectrum disorder. Nat Med 2015; 21:185.
  96. Robinson EB, Neale BM, Hyman SE. Genetic research in autism spectrum disorders. Curr Opin Pediatr 2015; 27:685.
  97. Woodbury-Smith M, Scherer SW. Progress in the genetics of autism spectrum disorder. Dev Med Child Neurol 2018; 60:445.
  98. Zhou J, Park CY, Theesfeld CL, et al. Whole-genome deep-learning analysis identifies contribution of noncoding mutations to autism risk. Nat Genet 2019; 51:973.
  99. C Yuen RK, Merico D, Bookman M, et al. Whole genome sequencing resource identifies 18 new candidate genes for autism spectrum disorder. Nat Neurosci 2017; 20:602.
  100. Trost B, Engchuan W, Nguyen CM, et al. Genome-wide detection of tandem DNA repeats that are expanded in autism. Nature 2020; 586:80.
  101. Mitra I, Huang B, Mousavi N, et al. Patterns of de novo tandem repeat mutations and their role in autism. Nature 2021; 589:246.
  102. Rosenberg RE, Law JK, Yenokyan G, et al. Characteristics and concordance of autism spectrum disorders among 277 twin pairs. Arch Pediatr Adolesc Med 2009; 163:907.
  103. Lichtenstein P, Carlström E, Råstam M, et al. The genetics of autism spectrum disorders and related neuropsychiatric disorders in childhood. Am J Psychiatry 2010; 167:1357.
  104. Colvert E, Tick B, McEwen F, et al. Heritability of Autism Spectrum Disorder in a UK Population-Based Twin Sample. JAMA Psychiatry 2015; 72:415.
  105. Sandin S, Lichtenstein P, Kuja-Halkola R, et al. The Heritability of Autism Spectrum Disorder. JAMA 2017; 318:1182.
  106. Hansen SN, Schendel DE, Francis RW, et al. Recurrence Risk of Autism in Siblings and Cousins: A Multinational, Population-Based Study. J Am Acad Child Adolesc Psychiatry 2019; 58:866.
  107. Cheng Y, Qin G, Dai X, Zhao Y. NPY1, a BTB-NPH3-like protein, plays a critical role in auxin-regulated organogenesis in Arabidopsis. Proc Natl Acad Sci U S A 2007; 104:18825.
  108. Bolton P, Macdonald H, Pickles A, et al. A case-control family history study of autism. J Child Psychol Psychiatry 1994; 35:877.
  109. Jorde LB, Hasstedt SJ, Ritvo ER, et al. Complex segregation analysis of autism. Am J Hum Genet 1991; 49:932.
  110. Piven J, Gayle J, Chase GA, et al. A family history study of neuropsychiatric disorders in the adult siblings of autistic individuals. J Am Acad Child Adolesc Psychiatry 1990; 29:177.
  111. Yin J, Schaaf CP. Autism genetics - an overview. Prenat Diagn 2017; 37:14.
  112. Satterstrom FK, Kosmicki JA, Wang J, et al. Large-Scale Exome Sequencing Study Implicates Both Developmental and Functional Changes in the Neurobiology of Autism. Cell 2020; 180:568.
  113. Boddaert N, Zilbovicius M, Philipe A, et al. MRI findings in 77 children with non-syndromic autistic disorder. PLoS One 2009; 4:e4415.
  114. Courchesne E, Mouton PR, Calhoun ME, et al. Neuron number and size in prefrontal cortex of children with autism. JAMA 2011; 306:2001.
  115. Hazlett HC, Gu H, Munsell BC, et al. Early brain development in infants at high risk for autism spectrum disorder. Nature 2017; 542:348.
  116. Lainhart JE. Advances in autism neuroimaging research for the clinician and geneticist. Am J Med Genet C Semin Med Genet 2006; 142C:33.
  117. Pelphrey K, Adolphs R, Morris JP. Neuroanatomical substrates of social cognition dysfunction in autism. Ment Retard Dev Disabil Res Rev 2004; 10:259.
  118. Chen R, Jiao Y, Herskovits EH. Structural MRI in autism spectrum disorder. Pediatr Res 2011; 69:63R.
  119. Stoner R, Chow ML, Boyle MP, et al. Patches of disorganization in the neocortex of children with autism. N Engl J Med 2014; 370:1209.
  120. Tang G, Gudsnuk K, Kuo SH, et al. Loss of mTOR-dependent macroautophagy causes autistic-like synaptic pruning deficits. Neuron 2014; 83:1131.
  121. Foster NE, Doyle-Thomas KA, Tryfon A, et al. Structural Gray Matter Differences During Childhood Development in Autism Spectrum Disorder: A Multimetric Approach. Pediatr Neurol 2015; 53:350.
  122. Bauman ML, Kemper TL. The neuropathology of the autism spectrum disorders: what have we learned? Novartis Found Symp 2003; 251:112.
  123. Supekar K, Kochalka J, Schaer M, et al. Deficits in mesolimbic reward pathway underlie social interaction impairments in children with autism. Brain 2018; 141:2795.
  124. Gervais H, Belin P, Boddaert N, et al. Abnormal cortical voice processing in autism. Nat Neurosci 2004; 7:801.
  125. Pierce K, Haist F, Sedaghat F, Courchesne E. The brain response to personally familiar faces in autism: findings of fusiform activity and beyond. Brain 2004; 127:2703.
  126. Piggot J, Kwon H, Mobbs D, et al. Emotional attribution in high-functioning individuals with autistic spectrum disorder: a functional imaging study. J Am Acad Child Adolesc Psychiatry 2004; 43:473.
  127. Wang AT, Dapretto M, Hariri AR, et al. Neural correlates of facial affect processing in children and adolescents with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry 2004; 43:481.
  128. Williams JH, Waiter GD, Gilchrist A, et al. Neural mechanisms of imitation and 'mirror neuron' functioning in autistic spectrum disorder. Neuropsychologia 2006; 44:610.
  129. Dalton KM, Nacewicz BM, Johnstone T, et al. Gaze fixation and the neural circuitry of face processing in autism. Nat Neurosci 2005; 8:519.
  130. Emerson RW, Adams C, Nishino T, et al. Functional neuroimaging of high-risk 6-month-old infants predicts a diagnosis of autism at 24 months of age. Sci Transl Med 2017; 9.
  131. McPartland J, Dawson G, Webb SJ, et al. Event-related brain potentials reveal anomalies in temporal processing of faces in autism spectrum disorder. J Child Psychol Psychiatry 2004; 45:1235.
  132. Bailey AJ, Braeutigam S, Jousmäki V, Swithenby SJ. Abnormal activation of face processing systems at early and intermediate latency in individuals with autism spectrum disorder: a magnetoencephalographic study. Eur J Neurosci 2005; 21:2575.
  133. Kasai K, Hashimoto O, Kawakubo Y, et al. Delayed automatic detection of change in speech sounds in adults with autism: a magnetoencephalographic study. Clin Neurophysiol 2005; 116:1655.
  134. Teder-Sälejärvi WA, Pierce KL, Courchesne E, Hillyard SA. Auditory spatial localization and attention deficits in autistic adults. Brain Res Cogn Brain Res 2005; 23:221.
  135. Clements CC, Zoltowski AR, Yankowitz LD, et al. Evaluation of the Social Motivation Hypothesis of Autism: A Systematic Review and Meta-analysis. JAMA Psychiatry 2018; 75:797.
  136. Gardener H, Spiegelman D, Buka SL. Prenatal risk factors for autism: comprehensive meta-analysis. Br J Psychiatry 2009; 195:7.
  137. Grether JK, Anderson MC, Croen LA, et al. Risk of autism and increasing maternal and paternal age in a large north American population. Am J Epidemiol 2009; 170:1118.
  138. Durkin MS, Maenner MJ, Newschaffer CJ, et al. Advanced parental age and the risk of autism spectrum disorder. Am J Epidemiol 2008; 168:1268.
  139. Sandin S, Hultman CM, Kolevzon A, et al. Advancing maternal age is associated with increasing risk for autism: a review and meta-analysis. J Am Acad Child Adolesc Psychiatry 2012; 51:477.
  140. Janecka M, Hansen SN, Modabbernia A, et al. Parental Age and Differential Estimates of Risk for Neuropsychiatric Disorders: Findings From the Danish Birth Cohort. J Am Acad Child Adolesc Psychiatry 2019; 58:618.
  141. Sandin S, Schendel D, Magnusson P, et al. Autism risk associated with parental age and with increasing difference in age between the parents. Mol Psychiatry 2016; 21:693.
  142. Hultman CM, Sandin S, Levine SZ, et al. Advancing paternal age and risk of autism: new evidence from a population-based study and a meta-analysis of epidemiological studies. Mol Psychiatry 2011; 16:1203.
  143. Kong A, Frigge ML, Masson G, et al. Rate of de novo mutations and the importance of father's age to disease risk. Nature 2012; 488:471.
  144. Mazina V, Gerdts J, Trinh S, et al. Epigenetics of autism-related impairment: copy number variation and maternal infection. J Dev Behav Pediatr 2015; 36:61.
  145. von Ehrenstein OS, Cui X, Yan Q, et al. Maternal Prenatal Smoking and Autism Spectrum Disorder in Offspring: A California Statewide Cohort and Sibling Study. Am J Epidemiol 2021; 190:728.
  146. Gardener H, Spiegelman D, Buka SL. Perinatal and neonatal risk factors for autism: a comprehensive meta-analysis. Pediatrics 2011; 128:344.
  147. Agrawal S, Rao SC, Bulsara MK, Patole SK. Prevalence of Autism Spectrum Disorder in Preterm Infants: A Meta-analysis. Pediatrics 2018; 142.
  148. Dachew BA, Mamun A, Maravilla JC, Alati R. Pre-eclampsia and the risk of autism-spectrum disorder in offspring: meta-analysis. Br J Psychiatry 2018; 212:142.
  149. Krakowiak P, Walker CK, Bremer AA, et al. Maternal metabolic conditions and risk for autism and other neurodevelopmental disorders. Pediatrics 2012; 129:e1121.
  150. Xiang AH, Wang X, Martinez MP, et al. Association of maternal diabetes with autism in offspring. JAMA 2015; 313:1425.
  151. Xiang AH. Association of Maternal Diabetes With Autism in Offspring. JAMA 2017; 317:537.
  152. Xiang AH, Wang X, Martinez MP, et al. Maternal Type 1 Diabetes and Risk of Autism in Offspring. JAMA 2018; 320:89.
  153. Hisle-Gorman E, Susi A, Stokes T, et al. Prenatal, perinatal, and neonatal risk factors of autism spectrum disorder. Pediatr Res 2018; 84:190.
  154. Fountain C, Winter AS, Bearman PS. Six developmental trajectories characterize children with autism. Pediatrics 2012; 129:e1112.
  155. Kim SA, Kasari C. Brief Report: Longitudinal Trajectory of Working Memory in School-Aged Children on the Autism Spectrum: Period of High Plasticity and "Late Bloomers". J Autism Dev Disord 2023.
  156. Harstad E, Hanson E, Brewster SJ, et al. Persistence of Autism Spectrum Disorder From Early Childhood Through School Age. JAMA Pediatr 2023; 177:1197.
Topic 595 Version 64.0

References

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟